Pharmaceuticals
Hong Kong ups disclosure requirements for biotech IPOs
The Hong Kong Stock Exchange has tightened disclosure requirements for companies looking to take advantage of two-year-old reforms permitting listings by pre-revenue biotech companies.
Japan biotech player raises $25m Series B
Japanese biotech developer Modulus Discovery has raised $25.5 million in Series B funding from a group of local VCs including SBI Investment.
Gaorong leads Series A for Chinese gene sequencing player
Qitan Technology, a Chinese gene sequencing company, has raised RMB100 million ($14 million) in Series A funding led by Gaorong Capital. Other backers include Yinxinggu Capital and Yahui Preision Medical Fund.
Hummingbird Bioscience gets $25m extended Series B
Hummingbird Bioscience, a Singapore and US-based drug developer with two cancer treatments on course to enter clinical trials, has received $25 million in an extended Series B round of funding led by the holding company of Korea’s SK Group.
Akeso Biopharma trades up after $333m Hong Kong IPO
Akeso Biopharma, a private equity-backed Chinese drug developer specializing in treatments that use the immune system to fight cancer, saw its stock jump 50% in early trading on the Hong Kong Stock Exchange following a HK$2.58 billion ($333 million) IPO.
Chinese drug developer Mabworks raises $159m Series C
Beijing Mabworks Biotech has raised a RMB1.13 billion ($159 million) Series C round led by CICC Capital, Lyzz Capital, CITIC Securities Investment, and Huge Capital.
CICC, GL Ventures join $66m round for Suzhou Ribo Life Science
Chinese drug developer Suzhou Ribo Life Science has raised RMB470 million ($66 million) in an extended Series C round led by China State-owned Capital Venture Capital Fund, CICC Capital and GL Ventures, the VC arm of Hillhouse Capital.
HighLight-backed Zentalis raises $165m in US IPO
Zentalis Pharmaceuticals, a US-based cancer drug developer, raised $165.2 million in its NASDAQ IPO, facilitating a liquidity event for Chinese healthcare investment specialist HighLight Capital.
Shanghai CDMO player gets $51m Series A
Zhenge Biotech – a Shanghai-based contract development and manufacturing organization (CDMO) for large molecule drugs – has raised $51 million in Series A funding led by Lyfe Capital.
Temasek leads $70m Series C for China's Abbisko Therapeutics
Temasek Holdings has led a $70 million Series C round for Chinese drug developer Abbisko Therapeutics.
Hillhouse leads $60m Series B for China biotech player
Hillhouse Capital has led a $60 million Series B round for China’s Iaso Biotherapeutics via its newly established VC unit GL Ventures.
PE-backed InnoCare raises $288m in Hong Kong IPO
InnoCare Pharma, a private equity-backed Chinese drug developer focused on treatments for cancer and autoimmune diseases, has raised HK$2.24 billion ($288 million) through a Hong Kong IPO.
Chinese drug developer RemeGen raises $100m
RemeGen, a Chinese drug developer, has raised a $100 million round led by Lilly Asia Ventures and Lake Bleu Capital.
China's Harbour BioMed gets $75m Series B extension
China-based biotech developer Harbour BioMed has closed an extended Series B round with a fresh $75 million commitment from a group of VCs. It initially raised $85 million in 2018.
China’s GenFleet Therapeutics raises $50m Series B
CDH Investments and Shenzhen Capital Group have co-led a $50 million Series B round for GenFleet Therapeutics, a Chinese drug developer.
China's CBC raises healthcare credit fund
CBC Group, a China-focused healthcare investor, has raised a $300 million credit fund that will issue financing to companies backed by royalties, revenue interests, and other cash flows.
First responders: China VCs on a healthcare crisis
The coronavirus outbreak has thrust Chinese healthcare services into the spotlight, prompting investors to identify to sub-segments with potential for significant growth
General Atlantic leads round for China's CANbridge Pharma
General Atlantic and WuXi AppTec, China’s leading contract research organization (CRO) WuXi AppTec, have led a $98 million Series D round for local drug developer CANbridge Pharmaceuticals.
HighLight hits $300m first close on China healthcare fund
Chinese healthcare-focused GP HighLight Capital has reached the first close of $300 million on its third US dollar-denominated fund, but further progress is likely to be delayed by the coronavirus outbreak.
CICC raises $229m for China healthcare fund
China's CICC Capital has raised RMB1.6 billion ($229 million) for its first fund dedicated to the biopharmaceutical space.
PE-backed Akeso Biopharma targets Hong Kong IPO
Chinese biotech player Akeso Biopharma has made a second attempt at filing for a Hong Kong IPO after its previous application was rejected last month for failing to meet regulatory requirements.
India’s Ascent invests in women’s pharma producer
Indian private equity firm Ascent Capital has invested INR1.25 billion ($17.5 million) in Naari Pharma, a women's health pharmaceutical business focused on hormonal generics.
AVCJ Awards 2019: Deal of the Year - Small Cap: AffaMed Therapeutics
CBC Group established biosimilars specialist AffaMed Therapeutics to remove uncertainties in the development process and to tap Chinese demand for affordable treatments
True North buys another unit from India's Glenmark
Mumbai-based Glenmark Pharmaceuticals has agreed to sell its gynecology operations in India and Nepal to a True North portfolio company for $16.2 million.